Dashboard
Manage Tickers

PTGX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

barclays-maintains-overweight-on-protagonist-therapeutics-raises-price-target-to-88
Barclays Maintains Overweight on Protagoni...
11/07/2025 15:47:43

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target...

citizens-maintains-market-outperform-on-protagonist-therapeutics-raises-price-target-to-102
Citizens Maintains Market Outperform on Pr...
11/07/2025 14:13:09

Citizens analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the ...

protagonist-therapeutics-q3-eps-062-beats-063-estimate-sales-4712m-beat-3636m-estimate
Protagonist Therapeutics Q3 EPS $(0.62) Be...
11/06/2025 21:38:42

truist-securities-maintains-buy-on-protagonist-therapeutics-raises-price-target-to-88
Truist Securities Maintains Buy on Protago...
10/28/2025 16:00:56

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the pr...

wedbush-maintains-outperform-on-protagonist-therapeutics-raises-price-target-to-86
Wedbush Maintains Outperform on Protagonis...
10/28/2025 13:11:44

Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target fro...

what-7-analyst-ratings-have-to-say-about-protagonist-therapeutics
What 7 Analyst Ratings Have To Say About P...
10/28/2025 11:44:49

btig-reiterates-buy-on-protagonist-therapeutics-maintains-82-price-target
BTIG Reiterates Buy on Protagonist Therape...
10/28/2025 09:23:17

BTIG analyst Julian Harrison reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $82 price target.

protagonist-therapeutics-announces-new-data-from-two-studies-of-icotrokinra-investigational-targeted-oral-peptide-that-precisely-blocks-il-23-receptor
Protagonist Therapeutics Announces New Dat...
10/27/2025 11:41:43

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with ...

citigroup-maintains-buy-on-protagonist-therapeutics-raises-price-target-to-96
Citigroup Maintains Buy on Protagonist The...
10/17/2025 15:29:08

Citigroup analyst Geoff Meacham maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from...

johnson--johnson-to-separate-orthopedics-business-boosts-annual-sales-outlook
Johnson & Johnson To Separate Orthopedics ...
10/14/2025 12:51:28

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthoped...

johnson--johnson-q3-preview-with-stock-near-all-time-highs-heres-what-to-watch
Johnson & Johnson Q3 Preview: With Stock N...
10/13/2025 16:27:44

Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.

fda-adds-new-warning-for-johnson--johnsons-cancer-cell-therapy
FDA Adds New Warning For Johnson & Johnson...
10/13/2025 14:30:41

FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the thera...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
10/10/2025 17:06:47

johnson--johnson-in-talks-to-acquire-protagonist-therapeutics-report
Johnson & Johnson In Talks To Acquire Prot...
10/10/2025 17:06:05

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug po...

protagonist-therapeutics-shares-resume-trade
Protagonist Therapeutics Shares Resume Trade
10/10/2025 15:33:28

protagonist-therapeutics-shares-halted-on-circuit-breaker-to-the-upside-stock-now-up-940
Protagonist Therapeutics Shares Halted On ...
10/10/2025 15:15:37

Core News & Articles
'Johnson & Johnson In Talks To Buy Protago...
10/10/2025 15:15:04

https://www.wsj.com/health/pharma/johnson-johnson-in-talks-to-buy-protagonist-therapeutics-38e0b69d

5-analysts-assess-protagonist-therapeutics-what-you-need-to-know
5 Analysts Assess Protagonist Therapeutics...
10/08/2025 12:01:55

hc-wainwright--co-reiterates-buy-on-protagonist-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Prot...
10/08/2025 10:21:42

HC Wainwright & Co. analyst Douglas Tsao reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $80 ...

protagonist-therapeutics-oral-il-23-blocker-icotrokinra-meets-phase-2b-goals-in-ulcerative-colitis-phase-3-trials-set-for-q4-2025
Protagonist Therapeutics' Oral IL-23 Block...
10/07/2025 12:12:09

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscop...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION